- Current report filing (8-K)
20 4월 2009 - 8:54PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 20,
2009 (April 19, 2009)
ALLOS THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
|
|
|
Westminster,
Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section 7
Regulation FD
Item 7.01 Regulation FD Disclosure.
On April 19, 2009,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release announcing the presentation, at the American Association for
Cancer Research Annual Meeting in Denver, Colorado, of new data demonstrating
the anticancer activity of the Companys investigational drug, pralatrexate, in
colon, ovarian, lung, prostate, and head and neck cancer cell lines.
The press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
In
accordance with General Instruction B.2. of Form 8-K, the information
presented under this Item 7.01 and attached as Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such a filing.
Section 9 Financial Statements
and Exhibits
Item 9.01
|
|
Financial Statements and Exhibits.
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
99.1
|
|
Press Release,
dated April 19, 2009, entitled Allos
Therapeutics Pralatrexate Demonstrates Anticancer Activity In Multiple
Cancer Cell Lines.
|
|
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: April 20, 2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
April 19, 2009, entitled Allos
Therapeutics Pralatrexate Demonstrates Anticancer Activity In Multiple
Cancer Cell Lines.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024